Home » RP-606 RIGHTS REVERT TO MEDIVIR
RP-606 RIGHTS REVERT TO MEDIVIR
Medivir announced today that all rights relating to the development of RP-606 (MIV-606), an oral antiviral being developed for the treatment of herpes zoster (shingles) and post-herpetic neuralgia (PHN), the chronic pain which is associated with shingles, have been reverted to Medivir. The reversion is effected by way of a mutual termination of the license agreement with Reliant Pharmaceuticals, Inc., which is now focusing on the marketing and development of its portfolio of cardiovascular products.
PrimeZone (http://www.primezone.com/newsroom/news.html?d=90994)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May